trending Market Intelligence /marketintelligence/en/news-insights/trending/fkoAroKvJoO43XHtFnXDqg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Assertio-West Therapeutic's hormonal disorder drug rejected by US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Assertio-West Therapeutic's hormonal disorder drug rejected by US FDA

The U.S. Food and Drug Administration rejected an application filed by Assertio Therapeutics Inc.'s partner West Therapeutic Development LLC, which sought approval of a long-acting version of the drug cosyntropin for a hormonal disorder.

Lake Forest, Ill.-based Assertio said West Therapeutic is seeking approval of the injectable formulation of long-acting cosyntropin for use as a diagnostic drug in screening patients presumed to have adrenocortical insufficiency — an uncommon disorder in which the adrenal glands fail to produce enough cortisol and aldosterone hormones.

In its complete response letter, the FDA determined that certain parameters relating to the drug's effects were not adequately achieved, Assertio said in an Oct. 21 press release.

Assertio President and CEO Arthur Higgins said the two companies will work together to determine how best to address the FDA's letter.